IMRN Stock: Immuron Limited Stock Price, Analysis & Insights
Get live imrn stock price $1.05, comprehensive Immuron Limited stock analysis, charts, news, and expert forecast. Real-time imrn stock data and investment insights.
Loading chart...
Company Overview
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Company Information
- CEO
- Steven George Lydeamore
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
Contact Information
- Website
- https://www.immuron.com.au
- Address
- 25-37 Chapman Street
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.60) may provide portfolio stability
Business Model & Strategy
Immuron Limited operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Steven George Lydeamore, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Immuron Limited competes in the Biotechnology within the broader Healthcare. With 6.0 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Immuron Limited provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Immuron Limited should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Immuron Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Immuron Limited
- ⚠Investors should consider how Immuron Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
6.01M
P/E Ratio
-1.76
Beta
0.60
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 6.01M market capitalization
- Trading Volume: 222.01K shares traded today
- Price Range: 52-week range of $1.00 - $2.48
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Immuron Limited
Immuron Limited (IMRN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 6.01M, the company represents a significant player in its market. The stock is currently trading at $1.05 with a negativedaily change of 5.80%.
The company's 7 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.76, beta of 0.60, and 52-week price range from $1.00 to $2.48when evaluating investment opportunities.
Why Invest in Immuron Limited?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Steven George Lydeamore
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.